IGC Pharma, Inc.
IGCHealthcare|Biotechnology|US
$0.20
+0.01 (+5.82%)
Tangible Book / Share
$0.01
Cash / Share
$0.00
About
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
Stock Price
-48.1%(1Y)
1M
-29.8%
3M
-22.1%
6M
-35.7%
YTD
-28.9%
1Y
-47.9%
3Y
-38.3%
5Y
-86.2%
Pipeline Summary
2 total trials1
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Completed: 1Active: 1
Active Trials (1)
Clinical Trial on Agitation in Alzheimer's Dementia
NCT05543681Alzheimer Disease
Phase 2Active
Enrollment: 164 participants
Key Facts
Market Cap$20.7M
Employees70 (+4% YoY)
CEORam Mukunda
IPO DateMay 24, 2006
Beta0.49
52-Week Range$0.08 – $0.4041
Avg Volume653,655
ExchangeAMEX
Websiteigcpharma.com
Ownership
Float89.4%
Shares Outstanding103.4M
Recent Insider Trades
Mukunda RamGIFT
Sep 25, 2026100,000 shares
Mukunda RamGIFT
Sep 25, 2026100,000 shares
GRIMALDI CLAUDIAGIFT
Sep 25, 2026150,000 shares
Mukunda RamAWARD
Jun 30, 20262,226,475 shares @ $0.27
GRIMALDI CLAUDIAAWARD
Jun 30, 20262,048,378 shares @ $0.27
Peers
Recent News
IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment
Oct 13, 2026 · accessnewswire.com
IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0%
Oct 3, 2026 · defenseworld.net
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026
Sep 28, 2026 · accessnewswire.com
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure
Aug 17, 2026 · accessnewswire.com
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
Aug 11, 2026 · accessnewswire.com
Data last updated: Nov 9, 2026, 04:14 AM